Pertuzumab is a monoclonal antibody that specifically targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in certain types of breast cancer. It is classified as an IgG1 kappa antibody and is designed to inhibit the dimerization of HER2 with other HER family receptors, thereby blocking downstream signaling pathways that promote tumor growth and survival. Pertuzumab is typically used in combination with other therapies, such as trastuzumab and chemotherapy, to enhance treatment efficacy in HER2-positive breast cancer patients. The substance is administered via intravenous infusion and has a molecular weight of approximately 148 kDa. Pertuzumab's mechanism of action not only helps in reducing tumor size but also plays a role in improving overall survival rates in affected patients. As with many biologic therapies, potential side effects may include infusion-related reactions, diarrhea, and cardiac issues, necessitating careful monitoring during treatment.

Pertuzumab

380610-27-5: Pertuzumab is a monoclonal antibody that specifically targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in certain types of breast cancer. It is classified as an IgG1 kappa antibody and is designed to inhibit the dimerization of HER2 with other HER family receptors, thereby blocking downstream signaling pathways that promote tumor growth and survival. Pertuzumab is typically used in combination with other therapies, such as trastuzumab and chemotherapy, to enhance treatment efficacy in HER2-positive breast cancer patients. The substance is administered via intravenous infusion and has a molecular weight of approximately 148 kDa. Pertuzumab's mechanism of action not only helps in reducing tumor size but also plays a role in improving overall survival rates in affected patients. As with many biologic therapies, potential side effects may include infusion-related reactions, diarrhea, and cardiac issues, necessitating careful monitoring during treatment.

Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2

<p>Blocks HER-2 heterodimerization; breast cancer therapy</p>

CAS 380610-27-5

Pertuzumab

Pertuzumab

Ref: TM-T9909

Pertuzumab

Ref: 3D-BP165593